Condition: HFrEF - Heart Failure With Reduced Ejection Fraction · Sponsor: Columbia University
This study evaluates the effects of the implantation and adjustment of the CVRx Barostim device in adult patients with heart failure with reduced ejection fraction who are receiving maximally tolerated doses of guideline directed medical and device therapies. The study aims to assess how therapy using this device affects heart function, symptoms, and exercise capacity, with particular focus on how the device affects blood flow and heart pressures during exercise. Information from this study may help inform patient selection and device management in patients with heart failure.
This description comes directly from the study's public registry record.
Morgan Smith, MD · 914-629-3121 · mds2225@cumc.columbia.edu
Always discuss trial participation with your own doctor first.
| University of California San Francisco Health | San Francisco, California, United States | Not Yet Recruiting |
| MedStar Health | Washington D.C., District of Columbia, United States | Not Yet Recruiting |
| University of Chicago Medical Center | Chicago, Illinois, United States | Not Yet Recruiting |
| Weill Cornell Medicine | New York, New York, United States | Not Yet Recruiting |
| Columbia University Irving Medical Center | New York, New York, United States | Recruiting |
| Montefiore Medical Center | New York, New York, United States | Not Yet Recruiting |
| Medical University of South Carolina Health | Charleston, South Carolina, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07335510